2. Search Result
Search Result
Results for "

lincosamide

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

8

Peptides

5

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1455
    Clindamycin
    10+ Cited Publications

    		 Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin
  • HY-B0408A
    Clindamycin hydrochloride
    Maximum Cited Publications
    15 Publications Verification

    		 Bacterial Antibiotic Infection Cancer
    Clindamycin (hydrochloride) is a semisynthetic lincosamide antibiotic, which inhibits protein synthesis by acting on the 50S ribosomal.
    Clindamycin hydrochloride
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-B1064
    Clindamycin phosphate
    4 Publications Verification

    Clindamycin 2-phosphate; U-28508

    		 Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis . Clindamycin phosphate has no cytotoxicity. Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .
    Clindamycin phosphate
  • HY-117660
    Lincomycin
    5 Publications Verification

    U-10149

    		 Antibiotic Bacterial DNA/RNA Synthesis Infection Metabolic Disease
    Lincomycin (U-10149) is an orally active lincosamide antibiotic. Lincomycin binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice .
    Lincomycin
  • HY-B0417A
    Lincomycin hydrochloride
    5 Publications Verification

    U10149A

    		 DNA/RNA Synthesis Antibiotic Bacterial Infection Metabolic Disease
    Lincomycin hydrochloride (U10149A) is an orally active lincosamide antibiotic. Lincomycin hydrochloride binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin hydrochloride can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin hydrochloride induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice .
    Lincomycin hydrochloride
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-B1358
    Lincomycin hydrochloride monohydrate
    5 Publications Verification

    U-10149 hydrochloride monohydrate

    		 DNA/RNA Synthesis Antibiotic Bacterial Infection Metabolic Disease
    Lincomycin (U-10149) hydrochloride monohydrate is an orally active lincosamide antibiotic. Lincomycin hydrochloride monohydrate binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin hydrochloride monohydrate can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin hydrochloride monohydrate induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice .
    Lincomycin hydrochloride monohydrate
  • HY-B1455S1
    Clindamycin-13C,d3

    		Isotope-Labeled Compounds Bacterial Antibiotic Parasite Infection
    Clindamycin- 13C,d3 is the 13C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin-13C,d3
  • HY-106597A
    Pirlimycin hydrochloride

    		Bacterial Antibiotic Infection
    Pirlimycin hydrochloride, a lincosamide antibiotic, is active against Gram-positive bacteria. Pirlimycin hydrochloride acts by inhibiting bacterial protein synthesis via binding with the 50S subunit of the ribosome .
    Pirlimycin hydrochloride
  • HY-106597
    Pirlimycin

    		Antibiotic Bacterial Infection
    Pirlimycin, a lincosamide antibiotic, is active against Gram-positive bacteria. Pirlimycin acts by inhibiting bacterial protein synthesis via binding with the 50S subunit of the ribosome .
    Pirlimycin
  • HY-B0408AR
    Clindamycin hydrochloride (Standard)

    		Reference Standards Bacterial Antibiotic Infection Cancer
    Clindamycin (hydrochloride) (Standard) is the analytical standard of Clindamycin (hydrochloride). This product is intended for research and analytical applications. Clindamycin (hydrochloride) is a semisynthetic lincosamide antibiotic, which inhibits protein synthesis by acting on the 50S ribosomal.
    Clindamycin hydrochloride (Standard)
  • HY-117963
    Lincosamine

    		Antibiotic Infection
    Lincosamine is a lincosamide antibiotic with activity that inhibits bacterial growth. Lincosamine is primarily produced by Streptomyces lincolnensis. Lincosamine has shown efficacy in combating certain bacterial infections, especially against Klebsiella pneumoniae. Lincosamine ranked among 14 other antimicrobial compounds in its activity against Klebsiella pneumoniae in a test .
    Lincosamine
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P11293
    DOTA-GGNle-CycMSHhex

    		Melanocortin Receptor Cancer
    DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .
    DOTA-GGNle-CycMSHhex
  • HY-B1455S
    Clindamycin-d3 hydrochloride

    		Bacterial Antibiotic Parasite Infection
    Clindamycin-d3 (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin-d3 hydrochloride
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-106597AR
    Pirlimycin hydrochloride (Standard)

    		Bacterial Reference Standards Antibiotic Infection
    Pirlimycin (hydrochloride) (Standard) is the analytical standard of Pirlimycin (hydrochloride). This product is intended for research and analytical applications. Pirlimycin hydrochloride, a lincosamide antibiotic, is active against Gram-positive bacteria. Pirlimycin hydrochloride acts by inhibiting bacterial protein synthesis via binding with the 50S subunit of the ribosome .
    Pirlimycin hydrochloride (Standard)
  • HY-B1455R
    Clindamycin (Standard)

    		Reference Standards Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .
    Clindamycin (Standard)
  • HY-117660R
    Lincomycin (Standard)

    U-10149 (Standard)

    		 Reference Standards DNA/RNA Synthesis Antibiotic Bacterial Infection Metabolic Disease
    Lincomycin (U-10149) (Standard) is the analytical reference standard of Lincomycin (HY-117660). This product is used for research and analytical applications. Lincomycin is an orally active lincosamide antibiotic. Lincomycin binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.
    Lincomycin (Standard)
  • HY-B1064A
    Clindamycin phosphate hydrochloride

    Clindamycin 2-phosphate hydrochloride; U-28508 hydrochloride

    		 Bacterial Antibiotic Parasite Infection Cancer
    Clindamycin phosphate (Clindamycin 2-phosphate) hydrochloride is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate hydrochloride is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate hydrochloride can be used for researching acne and bacterial vaginosis .
    Clindamycin phosphate hydrochloride
  • HY-W749665
    Clindamycin Hydrochloride-13C,d3

    		Isotope-Labeled Compounds Bacterial Antibiotic Cancer
    Clindamycin Hydrochloride- 13C,d3 is the deuterium and 13C-labeled Clindamycin hydrochloride (HY-B0408A). Clindamycin hydrochloride is a semisynthetic lincosamide antibiotic, which inhibits protein synthesis by acting on the 50S ribosomal.
    Clindamycin Hydrochloride-13C,d3
  • HY-B1064R
    Clindamycin phosphate (Standard)

    Clindamycin 2-phosphate (Standard); U-28508 (Standard)

    		 Reference Standards Bacterial Antibiotic Parasite Infection
    Clindamycin phosphate (Standard) is the analytical standard of Clindamycin phosphate. This product is intended for research and analytical applications. Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis .
    Clindamycin phosphate (Standard)
  • HY-117660S
    Lincomycin-d3

    U-10149-d3

    		 Isotope-Labeled Compounds DNA/RNA Synthesis Antibiotic Bacterial Infection Metabolic Disease
    Lincomycin-d3 (U-10149-d3) is the deuterium labeled Lincomycin. Lincomycin is an orally active lincosamide antibiotic. Lincomycin binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.
    Lincomycin-d3
  • HY-B1358R
    Lincomycin hydrochloride monohydrate (Standard)

    U-10149 hydrochloride monohydrate (Standard)

    		 Reference Standards DNA/RNA Synthesis Antibiotic Bacterial Infection Metabolic Disease
    Lincomycin (U-10149) hydrochloride monohydrate (Standard) is the analytical standard of Lincomycin hydrochloride monohydrate (HY-B1358). This product is intended for research and analytical applications. Lincomycin hydrochloride monohydrate is an orally active lincosamide antibiotic. Lincomycin hydrochloride monohydrate binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin hydrochloride monohydrate can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin hydrochloride monohydrate induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice.
    Lincomycin hydrochloride monohydrate (Standard)
  • HY-P1321A
    GR231118 TFA

    1229U91 TFA; GW1229 TFA

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA
  • HY-P11480
    TrkA/NGF-IN-1

    		Trk Receptor Neurological Disease
    TrkA/NGF-IN-1 (Peptide 19) is an inhibitor of protein-protein interactions between TrkA and NGF (IC50: 21 nM for human TrkA in PathHunter assay). TrkA/NGF-IN-1 shows an analgesic effect in a rat incisional pain model .
    TrkA/NGF-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: